Consider buying Oscar Health (OSCAR), which is currently undervalued with a Rule of 40 score of 63 and significant insider buying from the CEO at the $12.00 level. Hims & Hers Health (HIMS) offers a high-conviction play in personalized medicine, leveraging AI to disrupt traditional pharmacy models while maintaining strong growth and profitability metrics. For exposure to a real estate recovery, The Real Brokerage (REAX) is a top pick that is aggressively gaining market share from traditional brokers and is poised to surge if mortgage rates retreat toward 5%. Investors seeking high yield and dominant market positioning should look at Kaspi.kz (KSPI), a regional "super app" with a massive 89 Rule of 40 score and a dividend yield near 9.5%. Focus on these hyper-growth disruptors during market "flash sales" to capture high-quality assets at a significant discount relative to their gross profit growth.

Oscar Health (OSCAR)

• Described as the "ultimate cheapest stock" in the analyst's spreadsheet based on valuation metrics.
• Valuation Metrics: Enterprise Value over Gross Profit over Revenue Growth (EV/GP/RG) is 0.009 with a Rule of 40 score of 63.
• Growth Guidance: The company has guided for +61% revenue growth for the current year.
• Market Position: Operates in the Affordable Care Act (ACA) marketplace. Premiums in many areas have increased by over 30%, which benefits the company's top line.
• Insider Activity: The CEO recently bought $12 million worth of shares at $12.00/share.
• Operational Improvements: The company is focused on lowering costs and improving its Medical Loss Ratio (MLR) by being more conservative with spending estimates.

Takeaways

• Resilience: Health insurance is viewed as a "must-have" expense; consumers are more likely to give up car payments before insurance, providing a sticky customer base.
• Mispricing: The analyst believes the stock was unfairly battered by geopolitical tensions in the Middle East despite having no business exposure there.
• Profitability Potential: Improved MLR calculations are expected to drive higher profit margins in upcoming quarters.

The Real Brokerage (REAX)

• Identified as a "real estate recovery play" that has been ignored by the current market rally.
• Growth History: Has maintained a 50% year-over-year revenue growth rate for the past five years.
• Business Model: A cloud-based brokerage that recruits top-tier realtors by offering lower commission splits (15% vs. the industry standard 30%) and commission caps for high performers.
• Valuation: EV/GP/RG of 0.05 with a Rule of 40 score of 54.

Takeaways

• Market Share Gains: The company grows by "stealing" the top 10% of realtors from traditional mom-and-pop brokers who cannot compete with the tech-enabled, high-incentive model.
• Ancillary Services: While gross margins are low (9%), they are expanding into high-margin sectors like title insurance, mortgage referrals, and banking for agents.
• Interest Rate Catalyst: The analyst believes growth will "explode" once mortgage rates eventually drop back into the 5% range.

Hims & Hers Health (HIMS)

• Described as an "AI Pharmacy" that focuses on the customization of drugs and direct-to-consumer healthcare.
• AI Integration: Uses "MedMatch" AI to help providers determine the most effective prescriptions based on patient data.
• Pricing Model: Operates outside the traditional insurance system, offering treatments (anxiety, hair loss, weight loss) for $50–$80/month, which is often cheaper than insurance co-pays.
• Valuation: EV/GP/RG of 0.08 with a Rule of 40 score of 48.

Takeaways

• Zero-to-One Innovation: The company bundles doctor visits with prescriptions; if a doctor cannot help, the patient doesn't pay.
• Future Catalysts: Significant potential in peptides and a "painless needle" solution for blood draws and injections, which could disrupt traditional lab and weight-loss markets.
• Market Sentiment: Currently dismissed by some as just a "GLP-1 play," but the analyst argues the underlying AI-driven platform is undervalued.

Kaspi.kz (KSPI)

• A "Super App" based in Kazakhstan that recently expanded into Turkey by acquiring Hepsiburada (Epsi Bulara).
• Monopoly Status: Holds a dominant position in Kazakhstan, providing everything from e-commerce and payments to government services (driver's licenses, marriage certificates).
• Financial Performance: Revenue has nearly doubled in the last 18 months, yet the stock price has remained relatively flat.
• Valuation: Rule of 40 score of 89.

Takeaways

• Regional Powerhouse: The analyst views Kazakhstan as a winner in a high-priced oil environment and Turkey as a strategic growth hub.
• High Margins: Unlike many e-commerce firms, Kaspi originated as a bank, leading to very high EBITDA and gross margins.
• Income Component: The company pays a significant dividend (noted around 9.5%, though investors should verify currency fluctuations and specific dates).

Investment Themes & Sectors

• Hyper-Growth at a Discount: The primary theme is finding companies with high Rule of 40 scores (Growth + Profitability) that are trading at low valuations relative to their gross profit.
• The "Flash Sale" Market: The analyst warns that the current market is highly volatile ("a casino"), where stocks drop 10-15% on news/tweets and recover just as quickly, requiring investors to be ready to "buy the dip" quickly.
• Disruption of Traditional Models: A focus on companies using technology to undercut traditional incumbents, specifically in Insurance (Oscar), Real Estate (Real), and Healthcare (Hims).